Aristotle University Of Thessaloniki (AUTH)
Η συνδυασμένη δράση της 2-θεϊικής μερκαπτοαιθάνης και των πολυακόρεστων ω-3 λιπαρών οξέων στην αντιμετώπιση της ελκώδους κολίτιδας: πειραματική μελέτη σε επίμυες
Abstract
dc:descriptionUlcerative colitis (UC) is characterized by overproduction of reactive oxygen species (ROS) in the colon. In both humans and experimental models of UC, it has been shown that nuclear factor κB (NF-κΒ) is one of the most powerful and pleiotropic regulators of the inflammatory process. Additionaly, there is evidence that UC is characterized by high levels of inducible nitric oxide synthase (iNOS) activity and increased nitric oxide (NO).Better known as a chemotherapy adjuvant, sodium 2- mercaptoethane sulphonate (Mesna) is a drug with well-known antiinflammatory, antioxidant and antiapoptotic properties. A growing number of researchers focus on the study of natural products and ingredients, such as n-3 polyunsaturated fatty acids (n-3 PUFAs), which have strong antioxidant and anti-inflammatory action. However, the clinical benefits of n-3 PUFAs in UC remain at large unproven, while it has been reported that dietary enrichment of n-3 PUFAs in patients with UC can be harmful. Co-administration of n-3 PUFAs with antioxidants is an interesting strategy to address this adverse effect, that warrants further investigation.In the present study, the effect of the antioxidant drug Mesna, when administered alone or in combination with n-3 PUFAs (eicosapentaenoic-EPA and Docosahexaenoic acid-DHA) on the outcome of Dextran Sodium Sulfate (DSS)-induced UC in rats, was evaluated.A total of one hundred and fifteen (n=115) 2-3 months old male Wistar rats, weighing 230 - 280 gr, were used. The rats were randomly assigned, according to the therapeutic protocol, in 10 groups. For the induction of colitis, DSS was given in drinking water at a concentration of 5% (w / v) for 7 days. DSS was then removed from drinking water and rats were further treated orally (p.o), intraperitoneally (i.p) or intrarectally (i.r) for either 7 or 14 days with Mesna, n-3 PUFAs or both (MESNA p.o, n-3 PUFAs p.o, MESNA+ n-3 PUFAs p.o, MESNA p.r, n-3 PUFAs p.r, MESNA + n-3 PUFAs p.r, MESNA i.p, MESNA i.p + n-3 PUFAs p.o). Rats were euthanized at the end of each treatment period. Clinical disease activity index was recorded through-out the experiment. At necropsy, colon length was recorded and colorectal gross lesions were scored. Colitis was scored histologically, and the expression of myeloperoxidase (MPO), caspase-3, iNOS and NF-κΒ in colonic tissue was assessed by immunohistochemistry.Mesna and n-3 PUFAs improved the clinical outcome of DSS-induced colitis and decreased gross pathology indices of DSS colitis. Mesna alone was sufficient to significantly reduce colorectal tissue damage, when administered orally or intraperitoneally. Orally coadministered n-3 PUFAs enhanced this effect, resulting in the significant suppression of DSS colitis after 7 days, and a remarkable recovery of colorectal mucosa was evident after 14 days of treatment. The amelioration of colon pathology co-existed with a significant decrease of MPO expression, overexpression of iNOS and reduction of nuclear NF-κB p65 in inflammatory cells, and the suppression of apoptosis in colonic epithelial cells. The simultaneous administration of Mesna and n-3 PUFAs is particularly effective in ameliorating DSS colitis in rats, by reducing oxidative stress, inflammation and apoptosis, probably through a mechanism that involves the inhibition of NF-κB and overexpression of iNOS.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2016
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Triantafyllidis, Ioannis
- Τριανταφυλλίδης, Ιωάννης
Subjects
dc:subject × 14Rights
dc:rights- Statement dc:rights
-
- BY_NC
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/36910